Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis

The AAPS Journal
Dana L BakerSaloumeh Kadkhodayan Fischer

Abstract

Omalizumab (Xolair®) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Omalizumab is used to treat IgE-mediated diseases such as chronic idiopathic urticaria (CIU) and moderate to severe allergic asthma. In pre-marketing clinical trials in patients with asthma, anaphylaxis was reported in 3 of 3,507 (0.1%) patients. In post-marketing spontaneous reports, the frequency of anaphylaxis attributed to omalizumab use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006. To better understand the risk of anaphylaxis in patients with allergic asthma receiving omalizumab, a post-marketing pharmacosurveillance study was initiated in 2009. As part of this study, an assay was developed to detect antibodies of IgE isotype to omalizumab. Serum samples from patients in the study were evaluated using this assay. Our results indicated that there was no observable correlation between either anaphylaxis or skin test reactivity and the presence of antibodies of IgE isotype to omalizumab. Here, we discuss the development of this assay as well as the results of the immunogenicity assessment.

References

Jun 24, 2003·The American Journal of Gastroenterology·Adam CheifetzScott Plevy
Jun 18, 2004·The New England Journal of Medicine·Jonathan C W EdwardsTim Shaw
Mar 9, 2005·The Journal of Allergy and Clinical Immunology·Stephen HolgateColin Reisner
Mar 9, 2005·The Journal of Allergy and Clinical Immunology·Hugh A SampsonCarlos A Camargo
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Mar 30, 2007·Allergy and Asthma Proceedings·Benjamin I Oyefara, Sami L Bahna
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bert H O'NeilRichard M Goldberg
Oct 16, 2007·The Journal of Allergy and Clinical Immunology·Susan L LimbBadrul A Chowdhury
Mar 14, 2008·The New England Journal of Medicine·Christine H ChungThomas A E Platts-Mills
May 22, 2010·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Carlos IribarrenMark D Eisner
Jun 23, 2012·Methods in Molecular Biology·Robert F Kelley, Y Gloria Meng

❮ Previous
Next ❯

Citations

Oct 9, 2019·Expert Opinion on Drug Safety·Patrick Mitchell, Richard Leigh
Jan 30, 2020·Expert Review of Clinical Immunology·Kim Jackson, Sami L Bahna
Jun 17, 2020·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Koichi JingoKazuhisa Takahashi
Dec 5, 2019·Archives of Dermatological Research·Xie JianWang Aiwu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Expert Opinion on Biological Therapy
K Suresh BabuJaymin B Morjaria
Indian Journal of Dermatology
K V GodseNitin Nadkarni
Revue des maladies respiratoires
M Humbert, A B Tonnel
Paediatric Drugs
Amelia LicariGian Luigi Marseglia
© 2021 Meta ULC. All rights reserved